# LaNua Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lanua-medical

- Industry: Medical Devices & Equipment
- Headquarters: Galway, Ireland
- Website: www.lanuamedical.com/
- Total disclosed funding: $6.6M
- Latest round: Seed (Oct 11, 2024)
- Investors on record: 4

## About

Based in Galway, Ireland, and founded in 2024 by CEO and co-founder Tom Fitzmaurice, LaNua Medical Limited develops image-guided technologies for endovascular procedures. The company offers solutions to hospitals and clinics specializing in interventional radiology and vascular therapies. In October 2025, LaNua Medical Limited raised EUR 6 million in venture funding from returning investor Enterprise Ireland.

LaNua Medical specializes in the development of advanced image-guided technologies aimed at providing advanced endovascular solutions, particularly in embolization. The company's flagship product, the ECORE device, is intended to block blood flow to targeted tissue while facilitating the delivery of therapeutic agents, thereby reducing the risk of side effects associated with traditional embolization methods. This minimally invasive procedure is applicable for a range of clinical scenarios, including internal bleeding, benign and malignant tumors, and vascular diseases such as Pelvic Congestion Syndrome and varicocele. LaNua Medical targets healthcare providers in the MedTech sector, including hospitals and specialty clinics, with a focus on markets in Europe and the United States, where there is a significant demand for advanced medical technologies in interventional radiology and vascular therapies.

LaNua Medical's revenue model is built around the sale of its medical devices, particularly the ECORE embolization device. The company anticipates engaging in direct transactions with healthcare institutions, wherein hospitals and clinics will purchase the ECORE device for use in various interventional procedures.

The company will use the October 2025 funding to develop and test an embolization device for treating vascular disorders and cancers.

## Funding rounds

- Seed, Oct 11, 2024, $6.6M — Atlantic Bridge, Elkstone Ventures, Furthr VC, Enterprise Ireland

## Investors

- Atlantic Bridge (https://capitalatlas.ai/funds/atlantic-bridge) — Seed
- Elkstone Ventures (https://capitalatlas.ai/funds/elkstone-ventures) — Seed
- Furthr VC (https://capitalatlas.ai/funds/furthr-vc) — Seed
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Seed